|
|
| March 15, 2010: The EXPLORE-Xa Trial |
At ACC 2010, Dr. Michael D. Ezekowitz presents: A Randomized Clinical Trial of Three Doses
of a Long-Acting Oral Direct Factor Xa Inhibitor Betrixaban in Patients With Atrial
Fibrillation.
Consultant for Portola and Merck,Received grant support from Portola, has a sibling
employed by Merck.
[ Download video ] |
|
No comments have been submitted
|